Leading group of Baraclude generics, topped by Bukwang Pharm
Among the 62 generics entered in the market of ‘Baraclude,’ a drug expired in patent on the 10th of October, the leading group has been clarified.
According to the UBIST’s outpatient prescription data, there were about 10 companies exceeding monthly prescriptions of KRW 10 million; among them, B...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
